Free tool
FAERS Monitor: Tibsovo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211192 or its brand name (Tibsovo, Ivosidenib). Reports on generic versions are filed under their own applications.
Reports
2,178
Serious
1,366
63% of reports
Hospitalization
713
Death reported
229
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use656
- fatigue171
- nausea124
- diarrhoea123
- differentiation syndrome100
- malignant neoplasm progression89
- disease progression88
- product use issue88
- febrile neutropenia87
- drug ineffective83
- electrocardiogram qt prolonged78
- neutropenia76
- platelet count decreased76
- death74
- product dose omission issue74
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 4 |
| 2018 | 23 |
| 2019 | 236 |
| 2020 | 431 |
| 2021 | 398 |
| 2022 | 99 |
| 2023 | 176 |
| 2024 | 175 |
| 2025 | 290 |
| 2026 | 346 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,981 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| differentiation syndromeSignal | 100 | 1524.6 | 1239.9 | 130,205 |
| electrocardiogram qt prolongedSignal | 78 | 21.0 | 16.9 | 1,464 |
| febrile neutropeniaSignal | 87 | 12.7 | 10.3 | 926 |
| malignant neoplasm progressionSignal | 89 | 8.4 | 6.9 | 575 |
| off label useSignal | 656 | 7.2 | 6.8 | 3,672 |
| disease progressionSignal | 88 | 7.2 | 5.9 | 465 |
| platelet count decreasedSignal | 76 | 6.9 | 5.5 | 378 |
| neutropeniaSignal | 76 | 5.4 | 4.3 | 270 |
| product use issueSignal | 88 | 4.5 | 3.7 | 240 |
| product dose omission issueSignal | 74 | 2.4 | 1.9 | 62 |
| fatigueSignal | 171 | 2.1 | 1.8 | 104 |
| diarrhoea | 123 | 1.8 | 1.5 | 48 |
| nausea | 124 | 1.5 | 1.3 | 22 |
| death | 74 | 0.8 | 0.7 | 3 |
| drug ineffective | 83 | 0.6 | 0.5 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.